Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Dec;66(6):987–991. doi: 10.1038/bjc.1992.399

Adjuvant therapy in resectable gastric cancer.

H Bleiberg 1, B Gerard 1, P Deguiral 1
PMCID: PMC1978050  PMID: 1457367

Full text

PDF
987

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abe M., Takahashi M. Intraoperative radiotherapy: the Japanese experience. Int J Radiat Oncol Biol Phys. 1981 Jul;7(7):863–868. doi: 10.1016/0360-3016(81)90001-8. [DOI] [PubMed] [Google Scholar]
  2. Alcobendas F., Milla A., Estape J., Curto J., Pera C. Mitomycin C as an adjuvant in resected gastric cancer. Ann Surg. 1983 Jul;198(1):13–17. doi: 10.1097/00000658-198307000-00004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Allum W. H., Hallissey M. T., Kelly K. A. Adjuvant chemotherapy in operable gastric cancer. 5 year follow-up of first British Stomach Cancer Group trial. Lancet. 1989 Mar 18;1(8638):571–574. doi: 10.1016/s0140-6736(89)91607-3. [DOI] [PubMed] [Google Scholar]
  4. Allum W. H., Hallissey M. T., Ward L. C., Hockey M. S. A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report. British Stomach Cancer Group. Br J Cancer. 1989 Nov;60(5):739–744. doi: 10.1038/bjc.1989.350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Allum W. H., Powell D. J., McConkey C. C., Fielding J. W. Gastric cancer: a 25-year review. Br J Surg. 1989 Jun;76(6):535–540. doi: 10.1002/bjs.1800760604. [DOI] [PubMed] [Google Scholar]
  6. Blake J. R., Hardcastle J. D., Wilson R. G. Gastric cancer: a controlled trial of adjuvant chemotherapy following gastrectomy. Clin Oncol. 1981 Mar;7(1):13–21. [PubMed] [Google Scholar]
  7. Bleiberg H., Goffin J. C., Dalesio O., Buyse M., Pector J. C., Gignoux M., Roussel A., Samana G., Michel J., Gerard A. Adjuvant radiotherapy and chemotherapy in resectable gastric cancer. A randomized trial of the gastro-intestinal tract cancer cooperative group of the EORTC. Eur J Surg Oncol. 1989 Dec;15(6):535–543. [PubMed] [Google Scholar]
  8. Cady B., Rossi R. L., Silverman M. L., Piccione W., Heck T. A. Gastric adenocarcinoma. A disease in transition. Arch Surg. 1989 Mar;124(3):303–308. doi: 10.1001/archsurg.1989.01410030049009. [DOI] [PubMed] [Google Scholar]
  9. Clark J. L., Barcewicz P., Nava H. R., Goodwin P. S., Douglass H. O., Jr Adjuvant 5-FU and MeCCNU improves survival following curative gastrectomy for adenocarcinoma. Am Surg. 1990 Jul;56(7):423–427. [PubMed] [Google Scholar]
  10. Cunliffe W. J., Sugarbaker P. H. Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy. Br J Surg. 1989 Oct;76(10):1082–1090. doi: 10.1002/bjs.1800761030. [DOI] [PubMed] [Google Scholar]
  11. Dedrick R. L., Myers C. E., Bungay P. M., DeVita V. T., Jr Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978 Jan;62(1):1–11. [PubMed] [Google Scholar]
  12. Engstrom P. F., Lavin P. T., Douglass H. O., Jr, Brunner K. W. Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275). Cancer. 1985 May 1;55(9):1868–1873. doi: 10.1002/1097-0142(19850501)55:9<1868::aid-cncr2820550904>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  13. Estape J., Grau J. J., Lcobendas F., Curto J., Daniels M., Viñolas N., Pera C. Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10-year follow-up. Ann Surg. 1991 Mar;213(3):219–221. doi: 10.1097/00000658-199103000-00006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Fielding J. W., Ellis D. J., Jones B. G., Paterson J., Powell D. J., Waterhouse J. A., Brookes V. S. Natural history of "early" gastric cancer: results of a 10-year regional survey. Br Med J. 1980 Oct 11;281(6246):965–967. doi: 10.1136/bmj.281.6246.965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gunderson L. L., Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 1982 Jan;8(1):1–11. doi: 10.1016/0360-3016(82)90377-7. [DOI] [PubMed] [Google Scholar]
  16. Harrison J. D., Morris D. L., Ellis I. O., Jones J. A., Jackson I. The effect of tamoxifen and estrogen receptor status on survival in gastric carcinoma. Cancer. 1989 Sep 1;64(5):1007–1010. doi: 10.1002/1097-0142(19890901)64:5<1007::aid-cncr2820640506>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  17. Higgins G. A., Amadeo J. H., Smith D. E., Humphrey E. W., Keehn R. J. Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology, Group report. Cancer. 1983 Sep 15;52(6):1105–1112. doi: 10.1002/1097-0142(19830915)52:6<1105::aid-cncr2820520629>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  18. Huguier M., Destroyes J. P., Baschet C., Le Henand F., Bernard P. F. Gastric carcinoma treated by chemotherapy after resection: a controlled study. Am J Surg. 1980 Feb;139(2):197–199. doi: 10.1016/0002-9610(80)90253-6. [DOI] [PubMed] [Google Scholar]
  19. Kern K. A. Gastric cancer: a neoplastic enigma. J Surg Oncol Suppl. 1989;1:34–39. doi: 10.1002/jso.2930420508. [DOI] [PubMed] [Google Scholar]
  20. Koyama S., Ozaki A., Iwasaki Y., Sakita T., Osuga T., Watanabe A., Suzuki M., Kawasaki T., Soma T., Tabuchi T. Randomized controlled study of postoperative adjuvant immunochemotherapy with Nocardia rubra cell wall skeleton (N-CWS) and Tegafur for gastric carcinoma. Cancer Immunol Immunother. 1986;22(2):148–154. doi: 10.1007/BF00199130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lacave A. J., Izarzugaza I., Antón Aparicio L. M., Valle Pereda M., Gracia Marco J. M., Buesa J. M. Phase II clinical trial of cis-dichlorodiammineplatinum in gastric cancer. Am J Clin Oncol. 1983 Feb;6(1):35–38. [PubMed] [Google Scholar]
  22. Lise M., Nitti D., Buyse M., Marchet A., Fiorentino M., Dos Santos J. G., Duez N. Adjuvant FAM2 in resectable gastric cancer. Anticancer Res. 1989 Jul-Aug;9(4):1017–1021. [PubMed] [Google Scholar]
  23. Maehara Y., Moriguchi S., Sakaguchi Y., Emi Y., Kohnoe S., Tsujitani S., Sugimachi K. Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection. J Surg Oncol. 1990 Nov;45(3):169–172. doi: 10.1002/jso.2930450307. [DOI] [PubMed] [Google Scholar]
  24. Malaia L. T. Piatyi Ukrainskii s'ezd terapevtov. Vrach Delo. 1974 Oct;0(10):10–16. [PubMed] [Google Scholar]
  25. Milewski P. J., Bancewicz J. Improving the results of treating gastric cancer. BMJ. 1989 Jul 29;299(6694):278–279. doi: 10.1136/bmj.299.6694.278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Moertel C. G., Childs D. S., Jr, Reitemeier R. J., Colby M. Y., Jr, Holbrook M. A. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet. 1969 Oct 25;2(7626):865–867. doi: 10.1016/s0140-6736(69)92326-5. [DOI] [PubMed] [Google Scholar]
  27. Moertel C. G., Childs D. S., O'Fallon J. R., Holbrook M. A., Schutt A. J., Reitemeier R. J. Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol. 1984 Nov;2(11):1249–1254. doi: 10.1200/JCO.1984.2.11.1249. [DOI] [PubMed] [Google Scholar]
  28. Nakajima T., Fukami A., Ohashi I., Kajitani T. Long-term follow-up study of gastric cancer patients treated with surgery and adjuvant chemotherapy with mitomycin C. Int J Clin Pharmacol Biopharm. 1978 May;16(5):209–216. [PubMed] [Google Scholar]
  29. Nakajima T., Takahashi T., Takagi K., Kuno K., Kajitani T. Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. J Clin Oncol. 1984 Dec;2(12):1366–1371. doi: 10.1200/JCO.1984.2.12.1366. [DOI] [PubMed] [Google Scholar]
  30. Ochiai T., Sato H., Hayashi R., Asano T., Sato H., Yamamura Y. Postoperative adjuvant immunotherapy of gastric cancer with BCG-cell wall skeleton. 3- to 6-year follow up of a randomized clinical trial. Cancer Immunol Immunother. 1983;14(3):167–171. doi: 10.1007/BF00205355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Osband M. E., Hamilton D., Shen Y. J., Cohen E., Shlesinger M., Lavin P., Brown A., McCaffrey R. Successful tumour immunotherapy with cimetidine in mice. Lancet. 1981 Mar 21;1(8221):636–638. doi: 10.1016/s0140-6736(81)91554-3. [DOI] [PubMed] [Google Scholar]
  32. Popiela T., Zembala M., Kulig J., Czupryna A., Uracz W. Postoperative immunochemotherapy (BCG + 5-FU) in advanced gastric cancer. Anticancer Res. 1988 Nov-Dec;8(6):1423–1427. [PubMed] [Google Scholar]
  33. Preusser P., Wilke H., Achterrath W., Fink U., Lenaz L., Heinicke A., Meyer J., Meyer H. J., Buente H. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol. 1989 Sep;7(9):1310–1317. doi: 10.1200/JCO.1989.7.9.1310. [DOI] [PubMed] [Google Scholar]
  34. Schlag P. Adjuvant chemotherapy in gastric cancer. World J Surg. 1987 Aug;11(4):473–477. doi: 10.1007/BF01655812. [DOI] [PubMed] [Google Scholar]
  35. Serlin O., Wolkoff J. S., Amadeo J. M., Keehn R. J. Use of 5-fluorodeoxyuridine (FUDR) as an adjuvant to the surgical management of carcinoma of the stomach. Cancer. 1969 Aug;24(2):223–228. doi: 10.1002/1097-0142(196908)24:2<223::aid-cncr2820240203>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  36. Tønnesen H., Knigge U., Bülow S., Damm P., Fischerman K., Hesselfeldt P., Hjortrup A., Pedersen I. K., Pedersen V. M., Siemssen O. J. Effect of cimetidine on survival after gastric cancer. Lancet. 1988 Oct 29;2(8618):990–992. doi: 10.1016/s0140-6736(88)90743-x. [DOI] [PubMed] [Google Scholar]
  37. Wils J. A., Klein H. O., Wagener D. J., Bleiberg H., Reis H., Korsten F., Conroy T., Fickers M., Leyvraz S., Buyse M. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol. 1991 May;9(5):827–831. doi: 10.1200/JCO.1991.9.5.827. [DOI] [PubMed] [Google Scholar]
  38. Wils J., Bleiberg H. Current status of chemotherapy for gastric cancer. Eur J Cancer Clin Oncol. 1989 Jan;25(1):3–8. doi: 10.1016/0277-5379(89)90043-6. [DOI] [PubMed] [Google Scholar]
  39. Wils J., Bleiberg H., Dalesio O., Blijham G., Mulder N., Planting A., Splinter T., Duez N. An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer. J Clin Oncol. 1986 Dec;4(12):1799–1803. doi: 10.1200/JCO.1986.4.12.1799. [DOI] [PubMed] [Google Scholar]
  40. Youn J. K., Kim B. S., Min J. S., Lee K. S., Choi H. J., Lee Y. B., Lee D. W., Park I. S., Roh J. K., Chung J. B. Adjuvant treatment of operable stomach cancer with polyadenylic.polyuridylic acid in addition to chemotherapeutic agents: a preliminary report. Int J Immunopharmacol. 1990;12(3):289–295. doi: 10.1016/0192-0561(90)90084-z. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES